Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at approximately $1,399,273.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.33, for a total value of $747,375.11.
• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28.

Hims & Hers Health Stock Up 0.9 %

HIMS opened at $23.62 on Friday. The business has a fifty day moving average of $18.57 and a 200 day moving average of $18.33. The stock has a market cap of $5.07 billion, a P/E ratio of 53.68 and a beta of 1.06. Hims & Hers Health, Inc. has a 52-week low of $6.58 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the business posted ($0.04) EPS. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several recent analyst reports. Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Truist Financial raised their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Quantbot Technologies LP grew its stake in shares of Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares during the last quarter. IvyRock Asset Management HK Ltd acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $433,000. Swiss National Bank increased its stake in shares of Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares in the last quarter. Sei Investments Co. increased its position in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after buying an additional 37,890 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Hims & Hers Health during the 1st quarter worth $228,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.